David P. Perry serves as Independent Director of the Company. He has served as a member of our board of directors since June of 2016. He currently serves as President, Chief Executive Officer, and Director of Indigo. He is a serial entrepreneur who has founded and built three innovative companies in the last 20 years, leading the last two through successful IPOs and to multi-billion-dollar market capitalizations, and raising over $950 million, while generating significant returns for investors. David was most recently Chief Executive Officer and Co-Founder of Anacor Pharmaceuticals (NASDAQ: ANAC), a biopharmaceutical company discovering and developing novel small-molecule therapeutics to treat infectious and inflammatory diseases. The company was acquired by Pfizer Inc. (NYSE: PFE) in 2016 for approximately $5.2 billion. David previously co-founded and served as CEO of Chemdex (NASDAQ: CMDX), later creating its parent company Ventro Corporation (NASDAQ: VNTR), a business-to-business marketplace focused on the life sciences industry. At its peak, Ventro was valued at $11 billion and was later sold to Nexprise. David is also the Founder and Chairman of the San Francisco-based digital health startup Better Therapeutics (f/k/a FareWell). In 2000, David was named Entrepreneur of the Year in Northern California by Ernst and Young. He holds an M.B.A. from Harvard Business School and a B.S. in Chemical Engineering from the University of Tulsa. He also attended the United States Air Force Academy, where he was a National Merit Scholar.
As the Independent Director of Evelo Biosciences Inc, the total compensation of David Perry at Evelo Biosciences Inc is $110,860. There are 6 executives at Evelo Biosciences Inc getting paid more, with Balkrishan Gill having the highest compensation of $2,802,000.
David Perry is 52, he's been the Independent Director of Evelo Biosciences Inc since 2016. There are 14 older and 1 younger executives at Evelo Biosciences Inc. The oldest executive at Evelo Biosciences Inc is Stephen J. Carriere, 66, who is the VP & Chief Accounting Officer.
David's mailing address filed with the SEC is C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, CAMBRIDGE, MA, 02139.
Over the last 7 years, insiders at Evelo Biosciences Inc have traded over $41,656 worth of Evelo Biosciences Inc stock and bought 38,579,214 units worth $81,620,674 . The most active insiders traders include Ventures Fund Iv General Pa..., Noubar Afeyan és Ventures Fund Iv General Pa.... On average, Evelo Biosciences Inc executives and independent directors trade stock every 45 days with the average trade being worth of $19,676. The most recent stock trade was executed by Mark Bodmer on 7 November 2023, trading 6,625 units of EVLO stock currently worth $149.
evelo biosciences is dedicated to improving the lives of patients globally through the development of a new modality of medicines – monoclonal microbials. monoclonal microbials are orally delivered medicines that modulate systemic immunology and biology through direct interactions with human cells in the gut. these new medicines are broadly applicable across many diseases – including autoimmune, immunoinflammatory, metabolic, neurological, neuroinflammatory diseases and cancer. monoclonal microbials have the potential to fundamentally change traditional models of drug discovery and development. by finding and selecting naturally occurring monoclonal microbials with defined therapeutic effects, evelo can improve the speed, cost and success of drug discovery and development. evelo’s platform enables pharmacological intervention at all stages of disease with naturally occurring, safe and effective monoclonal microbials. evelo biosciences was conceived and created within venturelabs®, flag
Evelo Biosciences Inc executives and other stock owners filed with the SEC include: